Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company focused on type 2 diabetes that is resistant to standard care because of elevated cortisol. Its lead candidate, clofutriben, is a once-daily, oral selective 11β-HSD-1 inhibitor that lowers intracellular cortisol in key metabolic tissues. The drug has delivered improved glycemic control with a favorable safety and tolerability profile in early studies and is now being tested in the double-blind, Phase 2b CAPTAIN-T2D trial, with results expected in 2027. Beyond HbA1c reduction, clinical data suggest benefits on weight, blood pressure, lipids, bone metabolism, sleep and overall quality of life, addressing multiple facets of metabolic syndrome. The newly raised Series B funding will finance the Phase 2b program and further clinical development. Backing from premier life-science investors underscores confidence in Sparrow’s novel mechanism and market opportunity. The company remains pre-revenue as it advances its pipeline toward late-stage trials.

Total raised

$145M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2025